50/50 (2011) and Soft-Tissue Sarcoma of the Spine

Adam Lerner is 27 and writes for public radio in Seattle. He has back pain that will not settle. A scan finds a tumor lying along his spine. The word he is handed is neurofibrosarcoma, a sarcoma of the sheath around a nerve. His doctor dictates the diagnosis into a recorder while Adam sits in front of him. Chemotherapy follows, then surgery. His girlfriend leaves. His friend Kyle is crude, unreliable, and the only person who keeps treating him normally. His therapist is 24 and still in training. Will Reiser wrote the screenplay after his own diagnosis.

Spoilers throughout. Talking about the cancer storyline means talking about how it ends.

Adam's route in is the part worth noticing. Back pain, and it did not go away. Back pain is one of the most common complaints in medicine. It is almost never cancer. What made his different was persistence without an obvious cause, in a young person.

NCI describes the usual opening of a soft tissue sarcoma differently. The typical sign is a painless lump under the skin, often on an arm or a leg. Sarcomas that begin in the abdomen may cause nothing at all until they are very large. Pain and trouble breathing come later, when the tumor presses on nearby nerves, muscles, organs or blood vessels.

So the film's version, pain first and no lump, is possible rather than typical. A tumor sitting against the spine is one of the places where pain would arrive before anything could be felt.

Numbers help here, because the film gives none. The American Cancer Society projects 13,910 new soft tissue cancers in the United States in 2026, and 5,400 deaths; SEER publishes those projections next to its own measurements. NCI itself measures the rate at 3.5 new cases per 100,000 people per year. In 2023 an estimated 181,366 people in the country were living with a soft tissue cancer.

Stage at diagnosis matters. SEER reports that 56.8% of these cancers are found while still localized, and that 5-year relative survival for localized disease is 83.3%. Those two come from people diagnosed from 2016 through 2022.

There is nothing to be done in advance here. NCI's sarcoma page states that it does not have PDQ evidence-based information about screening for soft tissue sarcoma. No test is recommended for people without symptoms.

That is different from cancers where a screening program exists. For the small list of cancers where testing before symptoms is supported, see cancer screening. For sarcoma, the practical route is the unglamorous one: a lump that keeps growing, or pain that keeps going, gets examined.

Sarcoma is graded, not just staged. The 2017 AJCC and UICC system uses the three-tier FNCLCC grade, scored from how closely the tumor resembles normal tissue, how many cells are dividing, and how much dead tissue it contains.

PDQ is unusually blunt about the limits of stage here. It notes that staging is primarily used as a research tool and does not routinely drive decisions, apart from the factors already listed: subtype, grade, where the tumor sits, and whether disease is local, locally advanced or metastatic.

PDQ also lists what shifts the outlook: the subtype, the size and grade of the tumor, its location, whether surgery removed all of it, the person's age and general health, and whether the cancer has come back.

For sarcomas of the arms and legs, the goal is to remove the tumor and keep the limb. Radiation before or after surgery lowers the chance of local recurrence. In one randomized trial of 141 people treated with limb-sparing surgery, radiation was 45 Gy to a wide field plus an 18 Gy boost to the tumor bed. At up to 12 years, there was one local recurrence among the 70 people who received radiation, against 17 among the 71 who did not.

Chemotherapy after surgery is less settled. A meta-analysis of 1,568 individual patients across 14 trials of doxorubicin-based adjuvant treatment found an absolute 10% improvement in distant relapse-free interval. A later trial-level analysis put the absolute reduction in overall mortality at 6% for any chemotherapy and 11% for doxorubicin with ifosfamide. Then EORTC-62931 randomly assigned 351 people after local therapy and found no significant difference in either overall or relapse-free survival.

For the nerve-sheath sarcoma, NCI names one regimen specifically: ifosfamide with etoposide, both given on days 1, 2 and 3 and repeated every 21 days, at amounts the treating team calculates.

The googling of your own survival rate within the first hour. Chemotherapy as tedium rather than montage — a room, a chair, other people, hours. The friend who is useless and essential at once. The way everyone else's feelings become one more thing the patient has to manage. The therapist who is out of her depth and helps anyway.

Adam is handed a number as though it were a coin flip. Real estimates do not arrive that way. They are group figures with confidence intervals, built from people whose subtype, grade, tumor size and surgery were all different from each other.

The film also skips grade entirely, which is the single number a sarcoma team would be discussing. And it treats treatment as one undifferentiated block, when the actual sequence — biopsy, then surgery, then radiation timing, then a genuinely uncertain chemotherapy decision — is where the real conversations happen.

Cancer Explained carries no advertising and sells nothing. If this made a term clearer, or nudged you toward a question you had been avoiding, you can help keep it free for the next person. Support our work.

50/50 is a good film and a poor guide to sarcoma. Two things survive the translation. A change that persists without explanation is worth a conversation, even in a young person. And a percentage handed across a desk describes a crowd, not you.

• NCI — Soft Tissue Sarcoma Treatment (PDQ®), Health Professional Version
• NCI — Soft Tissue Sarcoma Treatment (PDQ®), Patient Version
• NCI — Soft Tissue Sarcoma, Patient Version overview
• SEER Cancer Stat Facts: Soft Tissue Cancer Including Heart

This page discusses 50/50 for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care. Spotted an error? Please email [email protected].